Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The New York University (NYU) has licensed Regulus Therapeutics for intellectual property that covers the methods of use in modulating microRNA-33a (miR-33a) and microRNA-33b (miR-33b) for metabolic diseases such as atherosclerosis and metabolic syndrome.
Subscribe to our email newsletter
The licensed technology relates to the discoveries that miR-33a and miR-33b down-regulate target genes involved in cholesterol transport and genes related to metabolic syndrome.
Additionally, Regulus also controls fundamental patent rights related to miR-33a and miR-33b, including compositions of matter for the miR-33a and miR-33b sequence and complement covered in the Tuschl III patent series and various chemically modified anti-miR compounds targeting miR-33a and miR-33b discovered by Regulus.
Regulus president and CEO Kleanthis Xanthopoulos said Regulus scientists and their collaborators at NYU have shown that dysregulation of specific microRNAs, including miR-33a and miR-33b, can drive metabolic disease processes linked to dyslipidemia and atherosclerosis, opening up the possibility of developing a new class of drugs to treat these conditions.